Novo Nordisk's deal with Korro is worth a total of $530 million in research and development (R&D) funding, milestone payments ...

“These are scams,” said Kenny Biddle, the chief investigator for the Center of Inquiry, an organization devoted to defending ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...

Nuvalent Inc. followed positive data during the European Society for Medical Oncology (ESMO) meeting with an upsized $500 million public offering. The Cambridge, Mass.-based firm is selling 5 million ...

U.S. total business inventories rose by 0.4% month-over-month in July compared to a 0.3% gain in June and topping market ...

Cambridge, USA-based Korro Bio has entered a collaboration with Denmark’s Novo Nordisk to advance the discovery and ...

Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on Korro Bio (KRRO – Research Report) and keeping the price target at ...

Korro Bio Inc. has established a collaboration with Novo Nordisk A/S to advance the discovery and development of new genetic medicines, initially to treat cardiometabolic diseases. The collaboration ...

Novo Nordisk isn’t done with the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two ...

Partnership leverages Korro’s proprietary OPERATM platform to enable its oligonucleotide-directed RNA edits into two undisclosed targets; ...

— We have everything you need: full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; ...